XTLB vs. THTX, MURA, IMMX, RPHM, CARM, RMTI, ANEB, DRRX, EQ, and CASI
Should you be buying XTL Biopharmaceuticals stock or one of its competitors? The main competitors of XTL Biopharmaceuticals include Theratechnologies (THTX), Mural Oncology (MURA), Immix Biopharma (IMMX), Reneo Pharmaceuticals (RPHM), Carisma Therapeutics (CARM), Rockwell Medical (RMTI), Anebulo Pharmaceuticals (ANEB), DURECT (DRRX), Equillium (EQ), and CASI Pharmaceuticals (CASI). These companies are all part of the "pharmaceutical preparations" industry.
Theratechnologies (NASDAQ:THTX) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, community ranking, analyst recommendations and institutional ownership.
XTL Biopharmaceuticals received 50 more outperform votes than Theratechnologies when rated by MarketBeat users. Likewise, 71.82% of users gave XTL Biopharmaceuticals an outperform vote while only 52.73% of users gave Theratechnologies an outperform vote.
In the previous week, Theratechnologies had 1 more articles in the media than XTL Biopharmaceuticals. MarketBeat recorded 2 mentions for Theratechnologies and 1 mentions for XTL Biopharmaceuticals. XTL Biopharmaceuticals' average media sentiment score of 1.82 beat Theratechnologies' score of 0.00 indicating that Theratechnologies is being referred to more favorably in the media.
XTL Biopharmaceuticals has lower revenue, but higher earnings than Theratechnologies.
4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. 29.0% of XTL Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
XTL Biopharmaceuticals has a net margin of 0.00% compared to XTL Biopharmaceuticals' net margin of -23.04%. XTL Biopharmaceuticals' return on equity of 0.00% beat Theratechnologies' return on equity.
Theratechnologies has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500. Comparatively, XTL Biopharmaceuticals has a beta of 1.24, suggesting that its stock price is 24% more volatile than the S&P 500.
Summary
Theratechnologies beats XTL Biopharmaceuticals on 7 of the 13 factors compared between the two stocks.
Get XTL Biopharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for XTLB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XTLB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
XTL Biopharmaceuticals Competitors List
Related Companies and Tools
